FGFR Inhibitor Compounds for Selective Kinase Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies targeting FGFRs and FGF signaling have limitations in effectively inhibiting tumor growth and angiogenesis, particularly in cancers where FGFR signaling is aberrant, due to resistance mechanisms and off-target effects.
Innovation Solution
Development of specific and potent compounds that selectively inhibit FGFR kinases, represented by formula (I), which modulate protein tyrosine kinase activity, thereby offering antiproliferative effects and potential therapeutic benefits in cancer treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies targeting FGFRs and FGF signaling are used, then tumor growth and angiogenesis are inhibited, but resistance mechanisms and off-target effects occur
Solution Approach 1:
The patent develops compounds with specific molecular structures (formula I) that are designed to interact selectively with FGFR kinases at particular binding sites. The compounds feature specific substituents (R1-R6, A, B, G, Z) that confer selectivity for FGFR over other kinases, thereby achieving local quality in terms of targeted binding while avoiding off-target effects on other protein kinases
Solution Approach 2:
The patent systematically varies molecular parameters including substituent types (halogen, alkyl, alkoxy, heterocyclic groups), ring structures (5-12 membered carbocyclic or heterocyclic rings), and linker lengths to optimize the balance between FGFR binding affinity and selectivity. These parameter changes enable the compounds to maintain potent inhibition while reducing resistance development through precise molecular recognition
2Adaptability or versatility
If broad-spectrum kinase inhibitors are used, then multiple kinase activities are inhibited, but selectivity for FGFR is reduced
Solution Approach 1:
The compounds of formula (I) are designed with specific local features including heterocyclic rings (pyridine, pyrimidine, triazole), specific substituent patterns, and molecular geometry that complement the FGFR kinase domain binding pocket. These local quality features enable selective interaction with FGFR while sparing other kinase families, achieving both targeted effectiveness and molecular precision
Solution Approach 2:
The patent employs specific molecular intermediaries including heterocyclic linkers (R5, R6 groups) and aromatic substituents (A, B rings) that act as mediators between the core molecular scaffold and the FGFR binding site. These intermediary structures facilitate selective recognition and binding to FGFR kinase domains while maintaining appropriate spacing and orientation for potent inhibition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds demonstrate significant inhibition of FGFR kinases, providing a targeted approach to cancer treatment by selectively inhibiting FGFR kinases, potentially overcoming resistance and off-target issues in existing therapies.
Implementation Method 1
Protein kinases are a class of proteins (enzymes) that regulate a variety of cellular functions. This is accomplished by phosphorylation of specific amino acids on protein substrates resulting in conformational alteration of the substrate protein.
Data Source
AI summary
A compound of formula (I), wherein R3, R4, G, B, M, and Z are as defined in the claims, and pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (1) possess utility as FGFR inhibitors and are useful in the treatment of a condition, where FGFR kinase inhibition is desired, such as cancer.